Report Detail

Pharma & Healthcare Global Neuromuscular Blocking Agent (NMBA) Market Insights, Forecast to 2025

  • RnM3819207
  • |
  • 06 November, 2019
  • |
  • Global
  • |
  • 119 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Study Coverage

    • 1.1 Neuromuscular Blocking Agent (NMBA) Product Introduction
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type
      • 1.4.2 Depolarizing
      • 1.4.3 Non-depolarizing
    • 1.5 Market by Application
      • 1.5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Pharmacy
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Neuromuscular Blocking Agent (NMBA) Market Size
      • 2.1.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2014-2025
      • 2.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2014-2025
    • 2.2 Neuromuscular Blocking Agent (NMBA) Growth Rate by Regions
      • 2.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Regions
      • 2.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers
      • 3.1.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers
      • 3.1.2 Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers
    • 3.2 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers
      • 3.2.1 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2014-2019)
    • 3.3 Neuromuscular Blocking Agent (NMBA) Price by Manufacturers
    • 3.4 Neuromuscular Blocking Agent (NMBA) Manufacturing Base Distribution, Product Types
      • 3.4.1 Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
      • 3.4.3 Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type

    • 4.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type
    • 4.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type
    • 4.3 Neuromuscular Blocking Agent (NMBA) Price by Type

    5 Breakdown Data by Application

    • 5.1 Overview
    • 5.2 Global Neuromuscular Blocking Agent (NMBA) Breakdown Data by Application

    6 North America

    • 6.1 North America Neuromuscular Blocking Agent (NMBA) by Country
      • 6.1.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Country
      • 6.1.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Neuromuscular Blocking Agent (NMBA) by Type
    • 6.3 North America Neuromuscular Blocking Agent (NMBA) by Application

    7 Europe

    • 7.1 Europe Neuromuscular Blocking Agent (NMBA) by Country
      • 7.1.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country
      • 7.1.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Neuromuscular Blocking Agent (NMBA) by Type
    • 7.3 Europe Neuromuscular Blocking Agent (NMBA) by Application

    8 Asia Pacific

    • 8.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Region
      • 8.1.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region
      • 8.1.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 South Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Thailand
      • 8.1.10 Malaysia
      • 8.1.11 Philippines
      • 8.1.12 Vietnam
    • 8.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Type
    • 8.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Application

    9 Central & South America

    • 9.1 Central & South America Neuromuscular Blocking Agent (NMBA) by Country
      • 9.1.1 Central & South America Neuromuscular Blocking Agent (NMBA) Sales by Country
      • 9.1.2 Central & South America Neuromuscular Blocking Agent (NMBA) Revenue by Country
      • 9.1.3 Brazil
    • 9.2 Central & South America Neuromuscular Blocking Agent (NMBA) by Type
    • 9.3 Central & South America Neuromuscular Blocking Agent (NMBA) by Application

    10 Middle East and Africa

    • 10.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Country
      • 10.1.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country
      • 10.1.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country
      • 10.1.3 Turkey
      • 10.1.4 GCC Countries
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Type
    • 10.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Application

    11 Company Profiles

    • 11.1 AbbVie
      • 11.1.1 AbbVie Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.1.5 AbbVie Recent Development
    • 11.2 GlaxoSmithKline
      • 11.2.1 GlaxoSmithKline Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.2.5 GlaxoSmithKline Recent Development
    • 11.3 Pfizer
      • 11.3.1 Pfizer Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.3.5 Pfizer Recent Development
    • 11.4 Hengrui Pharmaceutical
      • 11.4.1 Hengrui Pharmaceutical Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.4.5 Hengrui Pharmaceutical Recent Development
    • 11.5 Abbott Laboratories
      • 11.5.1 Abbott Laboratories Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.5.5 Abbott Laboratories Recent Development
    • 11.6 Fresenius Kabi
      • 11.6.1 Fresenius Kabi Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.6.5 Fresenius Kabi Recent Development
    • 11.7 Sandoz
      • 11.7.1 Sandoz Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.7.5 Sandoz Recent Development
    • 11.8 Somerset Therapeutics
      • 11.8.1 Somerset Therapeutics Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.8.5 Somerset Therapeutics Recent Development
    • 11.9 Guike Pharmaceutical
      • 11.9.1 Guike Pharmaceutical Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.9.5 Guike Pharmaceutical Recent Development
    • 11.10 Shanghai Pharmaceuticals
      • 11.10.1 Shanghai Pharmaceuticals Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Products Offered
      • 11.10.5 Shanghai Pharmaceuticals Recent Development
    • 11.11 Themis Medicare
    • 11.12 Nanjing King-Friend

    12 Future Forecast

    • 12.1 Neuromuscular Blocking Agent (NMBA) Market Forecast by Regions
      • 12.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions 2019-2025
    • 12.2 Neuromuscular Blocking Agent (NMBA) Market Forecast by Type
      • 12.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type 2019-2025
      • 12.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Type 2019-2025
    • 12.3 Neuromuscular Blocking Agent (NMBA) Market Forecast by Application
    • 12.4 North America Neuromuscular Blocking Agent (NMBA) Forecast
    • 12.5 Europe Neuromuscular Blocking Agent (NMBA) Forecast
    • 12.6 Asia Pacific Neuromuscular Blocking Agent (NMBA) Forecast
    • 12.7 Central & South America Neuromuscular Blocking Agent (NMBA) Forecast
    • 12.8 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Neuromuscular Blocking Agent (NMBA) Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      This report studies the global market size of Neuromuscular Blocking Agent (NMBA) in key regions like North America, Europe, China and Japan, focuses on the consumption of Neuromuscular Blocking Agent (NMBA) in these regions.
      This research report categorizes the global Neuromuscular Blocking Agent (NMBA) market by top players/brands, region, type and end user. This report also studies the global Neuromuscular Blocking Agent (NMBA) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AbbVie
      GlaxoSmithKline
      Pfizer
      Hengrui Pharmaceutical
      Abbott Laboratories
      Fresenius Kabi
      Sandoz
      Somerset Therapeutics
      Guike Pharmaceutical
      Shanghai Pharmaceuticals
      Themis Medicare
      Nanjing King-Friend

      Neuromuscular Blocking Agent (NMBA) market size by Type
      Depolarizing
      Non-depolarizing

      Neuromuscular Blocking Agent (NMBA) market size by Applications
      Hospital
      Clinic
      Pharmacy
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      Indonesia
      Thailand
      Malaysia
      Philippines
      Vietnam
      Central & South America
      Brazil
      Middle East & Africa
      Turkey
      GCC Countries
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Neuromuscular Blocking Agent (NMBA) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Neuromuscular Blocking Agent (NMBA) market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Neuromuscular Blocking Agent (NMBA) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Neuromuscular Blocking Agent (NMBA) submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Neuromuscular Blocking Agent (NMBA) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuromuscular Blocking Agent (NMBA) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Neuromuscular Blocking Agent (NMBA). Industry analysis & Market Report on Neuromuscular Blocking Agent (NMBA) is a syndicated market report, published as Global Neuromuscular Blocking Agent (NMBA) Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Neuromuscular Blocking Agent (NMBA) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,040.72
      4,561.09
      6,081.45
      3,535.85
      5,303.77
      7,071.70
      425,579.70
      638,369.55
      851,159.40
      278,394.87
      417,592.31
      556,789.74
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report